Treatment-resistant ovarian cancer represents one of oncology's most challenging frontiers, with most patients developing resistance to standard platinum-based chemotherapy and newer PARP inhibitors. The immunosuppressive tumor microenvironment creates an additional barrier, making the search for alternative therapeutic approaches increasingly urgent for the 22,000 women diagnosed annually in the United States.
Metformin, the widely prescribed diabetes medication, demonstrates dual anticancer mechanisms that could transform ovarian cancer treatment. The drug directly targets malignant cells by activating AMPK pathways, which disrupts cellular energy metabolism and triggers apoptosis in cancer cells. Beyond direct cytotoxicity, metformin reshapes the hostile tumor microenvironment by reprogramming macrophages from cancer-promoting M2 phenotypes to tumor-fighting M1 types, while simultaneously enhancing T-cell immune responses against ovarian tumors.
This metabolic reprogramming approach represents a paradigm shift from traditional cytotoxic strategies. Unlike conventional chemotherapy that often becomes ineffective due to resistance mechanisms, metformin's metabolic targeting may circumvent common escape routes cancer cells exploit. The drug's established safety profile from decades of diabetes use provides a significant advantage over novel compounds requiring extensive toxicity testing. However, the research remains largely preclinical, with human trials still determining optimal dosing, patient selection criteria, and combination strategies with existing therapies. The heterogeneous nature of ovarian cancer subtypes may limit universal efficacy, and questions persist about whether therapeutic doses differ substantially from standard diabetic treatment levels.